Cohort study evaluating the efficacy of denosumab to protect against aromatase inhibitor-induced bone loss in Japanese breast cancer patients.

Trial Profile

Cohort study evaluating the efficacy of denosumab to protect against aromatase inhibitor-induced bone loss in Japanese breast cancer patients.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Denosumab (Primary)
  • Indications Osteoporosis
  • Focus Therapeutic Use
  • Acronyms CYBORG003
  • Most Recent Events

    • 14 Nov 2016 Status changed from recruiting to discontinued.
    • 27 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top